Publication details

Analýza nákladů na 1. linii léčby metastatického kolorektálního karcinomu při podání režimů s bevacizumabem – data z reálné klinické praxe v České republice

Title in English The Cost Study of First- line Treatment of Metastatic Colorectal Carcinoma with Bevacizumab- containing Regimen in the Czech Republic
Authors

HRADECKÁ Irena ŘÍHOVÁ Barbora HOROVÁ R. DEMLOVÁ Regina

Year of publication 2014
Type Article in Periodical
Magazine / Source Klinická onkologie
MU Faculty or unit

Faculty of Medicine

Citation
web http://www.linkos.cz/casopis-klinicka-onkologie/archiv/detail/cislo/2014-08-15-4/#wizard-layout-headline-3
Field Oncology and hematology
Keywords drug costs; targeted molecular therapy; bevacizumab; antineoplastic agents; colorectal neoplasms
Description The assessment of direct cost of bevacizumab in the treatment of mCRC in the first line therapy in Czech Republic. Cost were obtained from a comprehensive cancer center. Cost were assessed from intiation of treatment to progression disease and/or to death.The majority of the total costs was formed by targeted drug therapy.

You are running an old browser version. We recommend updating your browser to its latest version.

More info